By Josh Beckerman Shares of molecular diagnostics company Biocept were down 46% following a Friday chapter 7 bankruptcy filing after the company considered…
Markets – MarketWatch
Biocept Falls 46% After Chapter 7 Filing Markets – MarketWatch
Related Posts
F.W. Thorpe Pretax Profit Rose, But Flags Slower Growth Ahead Markets – MarketWatch
By Christian Moess Laursen F.W. Thorpe said pretax profit and revenue rose in fiscal […]
Bank of Canada Gov. Macklem: Higher Yields ‘Not A Substitute’ for Inflation-Taming Rate-Policy Markets – MarketWatch
By Paul Vieira OTTAWA-Higher bond yields might tighten financial conditions in Canada but “they […]
Astria Therapeutics Shares Rise 8.9% After Licensing Deal for Dermatitis Treatment Markets – MarketWatch
By Ben Glickman Shares of Astria Therapeutics rose after the company secured a licensing […]